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GOVERNOR PATRICK ANNOUNCES NANOBIOTIX’S 
EXPANSION INTO MASSACHUSETTS 
Nano-medicine Company to Open First U.S. Office in Boston  
FRANCE – Friday, September 19, 2014 – Governor Deval Patrick today announced that 
Nanobiotix, a clinical-stage nano-medicine company pioneering novel approaches for 
the local treatment of cancer, will be opening its first U.S. office in Massachusetts. 
Governor Patrick met personally with officials from Nanobiotix at this year’s Bio 
Convention in San Diego this past June to explain the benefits of doing business in the 
Commonwealth. The announcement was made on the last day of the Governors 
Massachusetts-France Innovation Partnership Mission in Paris. 
 
“Massachusetts leads the world in life sciences thanks to our growth strategy of 
investing in education, innovation and infrastructure,” said Governor Patrick. “We 
welcome Nanobiotix, and we look forward to working with them to create jobs and 
opportunities in the Commonwealth.” 
 
Nanobiotix is focused on the development of NanoXray, a pipeline of products that are 
based on a physical mechanism of action. NanoXray products are built on the existing 
standard of care and can be used with existing radiation equipment available in almost 
every hospital worldwide.  
 
"The Patrick Administration is committed to growing the Massachusetts 
economy through investments in education, innovation and infrastructure, so that we 
can build on our position as the global leader in life sciences," said Greg Bialecki, the 
Secretary of Housing and Economic Development. “I congratulate Nanobiotix on 
opening their first U.S. office in Massachusetts and look forward to working with them as 
they grow.” 
 
To lead the development of the U.S. affiliate, Nanobiotix has appointed Patrick Tricoli as 
Vice President Corporate Development. Patrick has more than 25 years of experience 
within the pharmaceutical industry and joins Nanobiotix from SANOFI where he held a 
number of positions in both Corporate and Research Development.  
“The opening of a U.S. affiliate is a key strategic step for Nanobiotix’s corporate 
development. This exciting move expands our international presence to the U.S.,” said 
Nanobiotix CEO, Laurent Lévy. “Massachusetts is the ideal location for us to access the 
breadth of professional talent, innovative research and clinical expertise in the nano-
medicine field.” 
“We are excited to welcome Nanobiotix to the Massachusetts Life Sciences 
community,” said Susan Windham-Bannister, Ph.D., President & CEO of the 
Massachusetts Life Sciences Center, the agency charged with implementing Governor 
Patrick’s 10-year, $1 billion Life Sciences Initiative. “This company's presence in 
Massachusetts will contribute to our economy, and strengthen both our life sciences 
ecosystem and the growing business ties between Massachusetts and France.  I am 
confident that Nanobiotix will find all of the resources and partners it needs to thrive in 
Massachusetts and thank them for choosing to grow in Massachusetts.” 
About NANOBIOTIX  
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches 
for the local treatment of cancer. The company’s first-in-class, proprietary technology, 
NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment 
for cancer patients. NanoXray products are compatible with current radiotherapy 
treatments and are meant to treat a wide variety of cancers via multiple routes of 
administration. 
 
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical 
development for soft tissue sarcoma and locally advanced head and neck cancer. 
The company, based in Paris, France, has partnered with PharmaEngine for clinical 
development and commercialization of NBTXR3 in Asia.  
 
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: 
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). 
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